Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 23 2021 - 7:03AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2021
Commission file number: 001-35223
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
On February 23, 2021 the registrant issued the press
release which is filed as
Exhibit 1
to this Report on Form 6-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
BioLineRx Ltd.
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
Philip A. Serlin
|
|
|
|
Chief Executive Officer
|
|
Dated: February 23, 2021
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Sep 2023 to Sep 2024